STOCK TITAN
  1. Home
  2. News
  3. SNCE

Science 37 Holdings Inc - SNCE STOCK NEWS

Welcome to our dedicated news page for Science 37 Holdings (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Science 37 Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Science 37 Holdings's position in the market.

News
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Science 37 Holdings, Inc. announces granting of inducement equity awards under the 2022 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List
Rhea-AI Summary
Science 37's Chief Delivery Officer, Darcy Forman, has been honored with a spot on the PharmaVoice 100 list, highlighting the industry-wide impact of Science 37 and its positive contributions. Darcy's leadership has propelled the organization to new heights, achieving groundbreaking advancements in decentralized clinical trial conduct. Science 37's unique approach, the Metasite, enables patients to participate in clinical research from home. Patient recruitment and retention rates surpass industry standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
News
Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023
Rhea-AI Summary
Science 37 recognized in Gartner Hype Cycle for Life Science Clinical Development, 2023, for their innovative approach to digital trials. Digital trials are expected to improve trial quality, reduce costs, and enhance patient experience. Science 37's virtual site, MetasiteTM, allows patients to participate in trials remotely, leading to faster enrollment and improved retention rates. Adoption of decentralized clinical trials is increasing, driven by the recent FDA draft guidance. Positive impact on stock price expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
clinical trial
News
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
Rhea-AI Summary
Science 37 receives Frost & Sullivan Market Leadership Award in decentralized clinical trials industry
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
clinical trial
-
News
Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Science 37 Holdings, Inc. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.31%
Tags
conferences
-
News
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
Rhea-AI Summary
Science 37 Holdings, Inc. (SNCE) has been nominated for the 2023 Prix Galien USA Awards in the category of 'Best Digital Health Solution.' The company's Metasite™ has been recognized for its groundbreaking innovation in the clinical research industry, enabling universal trial access for patients through virtual trials. The nomination reflects Science 37's dedication to accelerating clinical research and making a positive impact on patients' lives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
none
News
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Science 37 Holdings, Inc. has announced the granting of inducement equity awards to non-executive employees. The awards consist of options to purchase 111,600 shares of Science 37 common stock at an exercise price of $0.44 per share. The options have a 10-year term and a four-year vesting schedule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Science 37 Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Science 37 reports Q2 2023 financial results, with gross bookings increasing by 33.0% to $38.2 million compared to the same period in 2022. Revenue decreased by 20% to $15.4 million. Gross profit remained steady at $5.4 million. Net loss improved by 20.5% to $19.6 million. Full year 2023 revenue guidance updated to approximately $60.0 million. Cash burn for Q3 2023 expected to be less than $10.0 million. Cash and Cash Equivalents as of June 30, 2023, were $65.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
earnings
-
News
Science 37 to Report Second Quarter 2023 Financial Results on August 8, 2023
Rhea-AI Summary
Science 37 Holdings, Inc. will report its second quarter 2023 financial results on August 8, 2023. The management team will host a conference call to discuss the results. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.32%
Tags
conferences earnings
News
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
Rhea-AI Summary
Science 37's Metasite chosen by Synlogic for virtual clinical trial technology and services in Phase III trial of labafenogene marselecobac for PKU treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.76%
Tags
partnership
Stock SNCE logo
Science 37 Holdings Inc

Nasdaq:SNCE

SNCE Rankings

N/A Ranked by Market Cap
#5224 Ranked by Stock Gains
N/A Ranked by Dividends

SNCE Stock Data

34.66M
4.13M
16.89%
52.18%
0.23%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States
Research Triangle Park

About SNCE

science 37 uses advanced telemedicine technology and patient-centric innovative networked clinical research models to rapidly accelerate biomedical discovery and bring down the costs of clinical trials. in addition to our own researchers, we also work closely with top physician-scientists and leading telemedicine companies. s37 offers full support and end-to-end services for networked clinical trials. if you are an investigator, an inventor, a small biotech company or a large pharmaceutical company, we can help you achieve your clinical trial goals faster and easier than ever before. based in los angeles, we are focused on the development of networked patient-centric models for clinical research to rapidly accelerate biomedical discovery. we leverage partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups, virtual e-consenting, mobile devices, and other technology companies to maximize efficiency. then, using design-thinking principles and rapid pr